Chemotherapy, as one of the primary ways to treat breast cancer, can put patients at high risk of side effects that can affect their adherence to treatment and quality of life. Alternative adjuvant therapy that can alleviate this effect can be beneficial for patients. A new study published in the journal Pharmacia showed that multi-strain probiotics can have impact on chemotherapy-related side effects through improved Karnofsky performance score and Blood Urea Nitrogen in breast cancer patients with chemotherapy.

Researchers from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) and local biotechnology company Intra-ImmuSG have announced promising outcomes from a Phase II clinical trial of a novel cancer immunotherapy, PRL3-zumab. Published in Cell Reports Medicine, the study shows PRL3-zumab safely slows disease progression in patients with advanced solid cancers unresponsive to existing treatments.

A single blood test, designed to pick up chemical signals indicative of the presence of many different types of cancer, could potentially thwart progression to advanced disease while the malignancy is still at an early stage and amenable to treatment in up to half of cases, suggests a modelling study published in the open access journal BMJ Open. Incorporating the test, formally known as a multi-cancer early detection test, or MCED for short, either yearly or biennially, could therefore improve outcomes for patients by intercepting disease progression, suggest the researchers.

Researchers looked at PFAS serum concentrations in health care workers for the first time and were surprised by what they found.